Chemkart FY26 Results: Net profit falls 16% YoY to ₹207.7 crore
- Standalone net profit fell 16.09% YoY to ₹207.72 crore in FY26
- Revenue from operations grew 4.58% to ₹2,125.95 crore
- Cost of material consumed surged 53.13%, compressing EBITDA margins
- Cash reserves jumped to ₹364.95 crore following successful IPO

*this image is generated using AI for illustrative purposes only.
Chemkart reported a 14.37% year-on-year decline in standalone net profit after tax (PAT) to ₹207.72 crore for FY26, despite revenue growth of 4.58%.
The nutraceutical ingredients supplier posted revenue from operations of ₹2,125.95 crore for the financial year ended March 31, 2026, up from ₹2,032.79 crore in the previous year. The company also successfully completed its Initial Public Offering (IPO) during the period, raising approximately ₹800.84 crore.
Financial Performance
The company's consolidated total income rose to ₹2,154.94 crore from ₹2,054.56 crore in FY25. However, profit before tax declined by 14.07% to ₹268.89 crore on a consolidated basis, down from ₹324.75 crore.
| Metric | FY26 (₹ Lakh) | FY25 (₹ Lakh) | Change |
|---|---|---|---|
| Revenue from Operations | 21,259.48 | 20,327.85 | +4.58% |
| Profit Before Tax | 2,800.61 | 3,271.13 | -14.38% |
| Net Profit After Tax | 2,077.20 | 2,475.49 | -16.09% |
What the Numbers Show
A significant divergence exists between top-line growth and bottom-line profitability. While revenue expanded moderately, the cost of material consumed surged by 53.13% to ₹114.63 crore, outpacing revenue growth significantly. This input cost inflation, combined with a 46.76% rise in employee benefit expenses to ₹31.20 crore, compressed margins. EBITDA fell 11.66% to ₹289.40 crore, with the EBITDA margin contracting by 251 basis points to 13.61%.
Balance Sheet and Capital Structure
The IPO proceeds materially strengthened the company’s liquidity position. Cash and cash equivalents skyrocketed to ₹364.95 crore, compared to just ₹27.83 crore at the end of FY25. Concurrently, the company reduced its short-term borrowings significantly, bringing them down to ₹49.53 crore from ₹169.26 crore.
Total reserves and surplus more than doubled to ₹1,189.59 crore, driven primarily by the addition of securities premium amounting to ₹541.78 crore from the public issue. The board did not recommend any dividend for the year, opting to reinvest profits to build a strong reserve base.
Operational Updates
The company continues to operate as a one-stop sourcing partner for nutraceutical ingredients, including amino acids, proteins, and vitamins. Management highlighted plans to scale up processing and blending operations at its Bhiwandi facility and integrate its wholly-owned subsidiaries, Easy Raw Materials Private Limited and Vinstar Biotech Private Limited, to capture greater value-added revenue.
Historical Stock Returns for Chemkart
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.94% | -8.75% | -0.54% | +64.13% | -9.54% | -29.47% |
How will Chemkart plan to mitigate the 53% surge in raw material costs to restore EBITDA margins in the upcoming fiscal year?
What specific synergies and revenue targets are expected from the integration of subsidiaries Easy Raw Materials and Vinstar Biotech?
Will the company deploy its strengthened cash reserves of ₹364.95 crore for vertical integration or potential M&A activities to secure supply chains?


































